IDH1 and acute myeloid leukemia: In an exploratory study of patients with treatment-naïve and R/R AML with IDH1 mutations [102], patients who received AZA/VEN/IVO had a CRc rate of 85–100% depending on dose intensity; however, this compares similarly to CRc rates of 67–100% with IVO/VEN alone.